RxDoctor Payments Data

Marilyn Stockman

Gerontology · Rio Rancho, NMNPI 1568130045

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.

$918in general payments, 2019–2025

Across 42 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$175
  • GSK$130
  • Amgen$130
  • AstraZeneca$95
  • Fresenius USA Marketing, Inc.$76
  • Aurinia Pharma U.S., Inc.$53
  • plus $260 from 7 others

What the payments were for

  • Food & beverage$91399%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$918 in reported general payments places this provider in the 85th percentile of 20 gerontology providers in New Mexico.

See all gerontology providers in New Mexico

Medicare billing

Part B allowed, 2024
$28,646
Medicare patients
137
Services billed
320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol106$77,247
VeltassaPatiromer Calcium Sorbitex13$10,250
Furosemide111$1,239
Potassium Chloride15$572
Bumetanide23$560
Lisinopril50$532
Losartan Potassium24$441
Amlodipine Besylate29$398
Metoprolol Succinate24$385
Tamsulosin Hcl15$335
Hydralazine Hcl15$312
Nifedipine ErNifedipine22$287
Pantoprazole Sodium12$203
Ciprofloxacin Hcl18$196
Atorvastatin Calcium16$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$95$77,247106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 20 gerontology providers in New Mexico.

Other gerontology in Rio Rancho

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →